Emotra’s CEO announces that he is stepping down. Emotra’s board of directors has appointed Marketing Manager Daniel Poté as the new CEO. Daniel will assume this new position immediately. Margit Ferm has stated that she wishes to step down as chairperson of the board,...
Yesterday, on October 17, 2018, Emotra hosted a training seminar for doctors and test leaders at a number of clinics that belong to a German psychiatric and psychotherapeutic hospital. This training is the start of a controlled introduction of the test in their...
Emotra has reached an important stage in its development. A few days ago, a scientific article was published based on a compilation of the results of earlier blind studies. It shows that hyporeactivity is a clear and strong marker for suicide risk. Furthermore, the...
A study conducted by Emotra’s Chief of Research and the inventor of EDOR®, Lars-Håkan Thorell, and the biostatistician Karl Wahlin demonstrates how strongly the company’s test identifies patients at risk of committing suicide. 180904- Emotra - PM - New...
The Board and CEO of Emotra AB (publ) hereby present the interim report for the first six months of 2018. 180822 Interim report Jan-June 2018
As we have previously announced, Japan is one of Emotra’s high-priority markets. The company has applied for patents in the EU, USA, Canada and Japan. The Japanese patent office has now informed us that Emotra’s Japanese patent application number 2016-516080 has been...
As we notified in a previous newsletter and our annual report, Emotra has changed its market introduction strategy for EDOR®. In the first and second quarter of 2018, we have been working the markets more directly and with a greater geographical focus. Given the...
The Board and CEO of Emotra AB (publ) hereby present the interim report for the first quarter 2018. Summary of the period January – March, 2018 180509- Interim report Jan-Mars 2018
The Annual General Meeting of EMOTRA AB (publ) was held today, May 9, 2018. The resolutions, summarised below, were all adopted with the necessary majority. 180509 - Emotra- PM - Communiqué AGM
Emotra AB (“Emotra”) hereby announces that an agreement has been reached with a group of researchers at the faculty of medicine at the University of Warsaw. The agreement concerns financial compensation for EDOR® tests in a clinical study. The study in question is a...
